Nothing Anemic About Ferahame: The Med Helps Amag Exceeds Street Expectations
This article was originally published in The Pink Sheet Daily
Executive Summary
With a broad label already in place, Amag plans to increase market for chronic kidney disease drug through label and geographic expansion.
You may also be interested in...
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
AMAG Pharmaceuticals announced April 1 it would team up with Takeda Pharmaceutical to commercialize its intravenous iron drug Feraheme (ferumoxytol) outside the US. A deal was not unexpected, as AMAG has signaled since winning approval from U.S. FDA in 2009 that the best way to maximize growth of Feraheme, especially in the European Union, is with a partner with global reach
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
Exclusive license adds to AMAG's cash reserves and further validates the anemia drug's safety profile
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
Exclusive license adds to AMAG's cash reserves and further validates the anemia drug's safety profile